NCT07313124

Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases

The Efficiency and Safety of Single Drug Versus Combinations of Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to study the efficiency and safety of using combinations of antihyperlipidemic agents with a single drug to treat cardiovascular diseases. The main questions it aims to answer are: * Which approach is more effective rosuvastatin monotherapy or rosuvastatin ezetimibe combination antihyperlipidemic for patients with cardiovascular diseases (CVDs)? * What medical problems do participants could when taking antihyperlipidemic drugs? Researchers will compare rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg to see the effectiveness and safety of these drugs in patients with CVDs. Participants will: * Patients will randomize to either rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg. * Patients will be followed up to 12 weeks after starting treatment. * All the patients will be subjected to: Full sheet taking, including detailed history and diagnosis of the case, Baseline Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) tests\& after 24 weeks of treatment, Lipid Profile, creatine kinase (CK) test, Creatine kinase-MB (CK-MB) test.

Conditions

• Cardiovascular Diseases (CVD)

Interventions

Type	Name	Description
DRUG	rosuvastatin drug	Patients randomized to receive rosuvastatin 20 mg
COMBINATION_PRODUCT	Patients received rosuvastatin ezetimibe10/10mg	Patients received rosuvastatin ezetimibe10/10mg

Timeline

• Start date: 2024-12-15
• Primary completion: 2025-11-20
• Completion: 2025-12-01
• First posted: 2025-12-31
• Last updated: 2026-01-05

Locations

1 site across 1 country: Egypt